Revelation Biosciences Inc. Announces Pricing of $6.2 Million Public Offering
- None.
- None.
Capital Raising and Dilution: The public offering by Revelation Biosciences Inc. of over a million shares, paired with warrants, is a substantial capital-raising effort. This influx of capital could bolster the company's balance sheet, potentially funding ongoing research and development projects or expanding operations. Investors should consider the dilutive effect of the additional shares on existing stockholders, which may depress the stock price in the short term. However, if the raised funds lead to successful product development, it could enhance long-term shareholder value.
Warrant Valuation: The warrants issued have an exercise price equivalent to the public offering price, which is an interesting choice. Typically, warrants are priced above the current share price to provide a future upside. The immediate exercisability of these warrants could lead to a quick increase in the number of shares outstanding if the stock price appreciates, further diluting existing shareholders but also potentially providing additional capital to the company if the warrants are exercised.
Market Response and Competitive Positioning: The market's response to Revelation's public offering will be indicative of investor confidence in the company's potential to harness trained immunity for disease treatment and prevention. It's essential to observe how this offering compares to similar capital-raising activities within the biotech sector. If the offering is well-received, it could signal market belief in the company's strategic direction and its potential to capture market share from competitors. Conversely, a lukewarm reception might suggest skepticism about the company's prospects or broader market conditions affecting investor sentiment.
Impact on Research and Development: Revelation Biosciences Inc.'s focus on trained immunity presents a novel approach in the life sciences sector. The capital raised from this offering could significantly advance their research initiatives. It's crucial to evaluate how these funds will be allocated towards their pipeline and whether they have a history of efficiently utilizing capital for R&D. The success of their research efforts will be a key driver in their long-term viability and ability to bring innovative treatments to market, which in turn, could substantially affect their future revenue streams and market position.
Roth Capital Partners is acting as sole placement agent for the offering.
The gross proceeds to the Company from the offering are expected to be approximately
The securities described above are being offered pursuant to a registration statement on Form S-1 (File No. 333-276232), as amended, that was declared effective by the
This press release does not constitute an offer to sell or the solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or other jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or other jurisdiction.
About Revelation Biosciences Inc.
Revelation Biosciences, Inc. is a life sciences company focused on harnessing the power of trained immunity for the prevention and treatment of disease using its proprietary formulation, Gemini. Revelation has multiple ongoing programs to evaluate Gemini, including GEMINI-SSI as a prevention for hospital acquired infection, GEMINI-AKI as a prevention for acute kidney injury, and GEMINI-CKD for the treatment of chronic kidney disease.
For more information on Revelation, please visit www.RevBiosciences.com.
Forward-Looking Statements
This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These forward-looking statements are generally identified by the words "anticipate", "believe", "expect", "estimate", "plan", "outlook", and "project" and other similar expressions. We caution investors that forward-looking statements are based on management’s expectations and are only predictions or statements of current expectations and involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from those anticipated by the forward-looking statements. Revelation cautions readers not to place undue reliance on any such forward looking statements, which speak only as of the date they were made. The following factors, among others, could cause actual results to differ materially from those described in these forward-looking statements: the ability of Revelation to meet its financial and strategic goals, due to, among other things, competition; the ability of Revelation to grow and manage growth profitability and retain its key employees; the possibility that the Revelation may be adversely affected by other economic, business, and/or competitive factors; risks relating to the successful development of Revelation’s product candidates; the ability to successfully complete planned clinical studies of its product candidates; the risk that we may not fully enroll our clinical studies or enrollment will take longer than expected; risks relating to the occurrence of adverse safety events and/or unexpected concerns that may arise from data or analysis from our clinical studies; changes in applicable laws or regulations; expected initiation of the clinical studies, the timing of clinical data; the outcome of the clinical data, including whether the results of such study is positive or whether it can be replicated; the outcome of data collected, including whether the results of such data and/or correlation can be replicated; the timing, costs, conduct and outcome of our other clinical studies; the anticipated treatment of future clinical data by the FDA, the EMA or other regulatory authorities, including whether such data will be sufficient for approval; the success of future development activities for its product candidates; potential indications for which product candidates may be developed; the ability of Revelation to maintain the listing of its securities on NASDAQ; the expected duration over which Revelation’s balances will fund its operations; and other risks and uncertainties described herein, as well as those risks and uncertainties discussed from time to time in other reports and other public filings with the SEC by Revelation.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240201416207/en/
Sandra Vedrick
Vice President, Investor Relations & Human Resources
Revelation Biosciences Inc.
Email: svedrick@revbiosciences.com
and
Chester Zygmont, III
Chief Financial Officer
Revelation Biosciences Inc.
Email: czygmont@revbiosciences.com
Source: Revelation Biosciences Inc.
FAQ
What is the ticker symbol for Revelation Biosciences Inc.?
How many shares are being offered in the public offering?
What is the offering price per share?
What are the warrants associated with the offering?